Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000175201 | SCV000226645 | uncertain significance | not provided | 2015-01-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001852143 | SCV002188008 | uncertain significance | Dilated cardiomyopathy 1W | 2021-12-10 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with glutamine, which is neutral and polar, at codon 818 of the VCL protein (p.Leu818Gln). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with VCL-related conditions. ClinVar contains an entry for this variant (Variation ID: 194760). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002444699 | SCV002732778 | uncertain significance | Cardiovascular phenotype | 2025-01-01 | criteria provided, single submitter | clinical testing | The c.2453T>A (p.L818Q) alteration is located in exon 17 (coding exon 17) of the VCL gene. This alteration results from a T to A substitution at nucleotide position 2453, causing the leucine (L) at amino acid position 818 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |